Chen Q, Jain N, Ayer T, et al. Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States. J Clin Oncol. 2017;35:166–74. https://doi.org/10.1200/JCO.2016.68.2856.

Article  CAS  PubMed  Google Scholar 

Waweru C, Kaur S, Sharma S, Mishra N. Health-related quality of life and economic burden of chronic lymphocytic leukemia in the era of novel targeted agents. Curr Med Res Opin. 2020;36:1481–95. https://doi.org/10.1080/03007995.2020.1784120.

Article  CAS  PubMed  Google Scholar 

National Cancer Institute. Cancer stat facts: leukemia—chronic lymphocytic leukemia (CLL). Available at: https://seer.cancer.gov/statfacts/html/clyl.html. Accessed 20 Mar 2026.

American Cancer Society. Key statistics for chronic lymphocytic leukemia. Available at: https://www.cancer.org/cancer/types/chronic-lymphocytic-leukemia/about/key-statistics.html. Accessed 20 Mar 2026.

Goyal RK, Nagar SP, Kabadi SM, Le H, Davis KL, Kaye JA. Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: real-world evidence from the Medicare population. Cancer Med. 2021;10:2690–702. https://doi.org/10.1002/cam4.3855.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kabadi SM, Goyal RK, Nagar SP, Kaye JA, Davis KL. Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States. Cancer Med. 2019;8:3803–10. https://doi.org/10.1002/cam4.2268.

Article  PubMed  PubMed Central  Google Scholar 

Mansfield C, Masaquel A, Sutphin J, et al. Patients’ priorities in selecting chronic lymphocytic leukemia treatments. Blood Adv. 2017;1:2176–85. https://doi.org/10.1182/bloodadvances.2017007294.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematol Am Soc Hematol Educ Program. 2020;2020:336–45. https://doi.org/10.1182/hematology.2020000118.

Article  Google Scholar 

Paydas S. Management of adverse effects/toxicity of ibrutinib. Crit Rev Oncol Hematol. 2019;136:56–63. https://doi.org/10.1016/j.critrevonc.2019.02.001.

Article  PubMed  Google Scholar 

Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017;92:946–65. https://doi.org/10.1002/ajh.24826.

Article  CAS  PubMed  Google Scholar 

Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745–60. https://doi.org/10.1182/blood-2017-09-806398.

Article  CAS  PubMed  Google Scholar 

Cochrane T, Enrico A, Gomez-Almaguer D, et al. Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial. Leuk Lymphoma. 2022;63:304–14. https://doi.org/10.1080/10428194.2021.1986217.

Article  CAS  PubMed  Google Scholar 

Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19:65–75. https://doi.org/10.1016/S1470-2045(17)30909-9.

Article  CAS  PubMed  Google Scholar 

Seymour JF, Mobasher M, Kater AP. Venetoclax-rituximab in chronic lymphocytic leukemia. N Engl J Med. 2018;378:2143–4. https://doi.org/10.1056/NEJMc1805135.

Article  PubMed  Google Scholar 

Kater AP, Wu JQ, Kipps T, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study. J Clin Oncol. 2020;38:4042–54. https://doi.org/10.1200/JCO.20.00948.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hillmen P, Rawstron AC, Brock K, et al. Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study. J Clin Oncol. 2019;37:2722–9. https://doi.org/10.1200/JCO.19.00894.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311–22. https://doi.org/10.1056/NEJMoa1513257.

Article  CAS  PubMed  Google Scholar 

Tambaro FP, Wierda WG. Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations. Lancet Haematol. 2020;7:e168–76. https://doi.org/10.1016/S2352-3026(19)30253-4.

Article  PubMed  Google Scholar 

Davids MS, Hallek M, Wierda W, et al. Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed/refractory chronic lymphocytic leukemia. Clin Cancer Res. 2018;24:4371–9. https://doi.org/10.1158/1078-0432.CCR-17-3761.

Article  CAS  PubMed  Google Scholar 

Ysebaert L, Troussard X, Levy V, et al. Real-world efficacy and safety of venetoclax alone and in combination with rituximab in patients with chronic lymphocytic leukemia: interim results of the Verone study. Blood. 2022;140(Suppl 1):I2395–6. https://doi.org/10.1182/blood-2022-162319.

Article  Google Scholar 

Ysebaert L, Troussard X, Levy V, et al. Real-life efficacy and safety of venetoclax monotherapy in relapsed/refractory chronic lymphocytic leukemia: interim analysis of multicentric study Verone. HemaSphere. 2022;6:570–1. https://doi.org/10.1097/01.HS9.0000845572.12203.da.

Article  Google Scholar 

Scarfo L, Albi E, Quaglia FM. An observational study on patients with relapsed/refractory chronic lymphocytic leukemia treated with venetoclax-based regimens outside clinical trials in Italy (GIMEMA CLL1920). Blood. 2021;138(Suppl 1):3746. https://doi.org/10.1182/blood-2021-148696.

Article  Google Scholar 

Laurenti L, Scarfò L, Frustaci AM, et al. Real-world evidence on venetoclax in chronic lymphocytic leukemia: the Italian experience. Hematol Oncol. 2023;41:621–30. https://doi.org/10.1002/hon.3122.

Article  CAS  PubMed  Google Scholar 

Mato AR, Thompson M, Allan JN, et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018;103:1511–7. https://doi.org/10.3324/haematol.2018.193615.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eyre TA, Roeker LE, Fox CP, et al. The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukemia. Br J Haematol. 2020;188:918–23. https://doi.org/10.1111/bjh.16271.

Article  CAS  PubMed  Google Scholar 

Roeker LE, Fox CP, Eyre TA, et al. Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice. Clin Cancer Res. 2019;25:4264–70. https://doi.org/10.1158/1078-0432.CCR-19-0361.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Samuels C, Abbott D, Niemiec S, et al. Evaluation and associated risk factors for neutropenia with venetoclax and obinutuzumab in the treatment of chronic lymphocytic leukemia. Cancer Rep. 2022;5:e1505. https://doi.org/10.1002/cnr2.1505.

Article  CAS  Google Scholar 

Herishanu Y, Goldschmidt N, Itchaki G, et al. Real-world effectiveness of venetoclax-based regimens in patients with chronic lymphocytic leukemia in Israel: update from the multicenter prospective REVEAL study. HemaSphere. 2023;7(Suppl 3):e4428024. https://doi.org/10.1097/01.HS9.0000969508.44280.24.

Article  PubMed Central  Google Scholar 

Ma S, Seymour JF, Brander DM, et al. Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy. Blood. 2021;138:836–46. https://doi.org/10.1182/blood.2020009578.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005;17:393–403. https://doi.org/10.1016/j.molcel.2004.12.030.

Article